Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus PANMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus PANMYCIN.
DOXY 100 vs PANMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic